About this item:

102 Views | 131 Downloads

Author Notes:

Address for Correspondence: Lisa M. Cranmer, MD, MPH, Department of Pediatrics, Emory University School of Medicine and Children’s Healthcare of Atlanta, 2015 Uppergate Drive NE, Atlanta, GA 30322. Telephone: (404) 727-2905; Fax: (404) 727-9223; lisa.cranmer@emory.edu.

We thank study participants and FIND for provision of QuantiFERON®-TB Gold In-Tube ELISA tubes and kits.

The authors declare no conflicts of interest.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.


Research Funding:

Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network was provided by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under Award Numbers UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC) and UM1AI106716 (IMPAACT LOC), with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH).


  • Science & Technology
  • Life Sciences & Biomedicine
  • Immunology
  • Infectious Diseases
  • Pediatrics
  • tuberculosis
  • HIV
  • children
  • tuberculin

High Incidence of Tuberculosis Infection in HIV-exposed Children Exiting an Isoniazid Preventive Therapy Trial

Show all authors Show less authors

Journal Title:

Pediatric Infectious Disease Journal


Volume 37, Number 10


, Pages E254-E256

Type of Work:

Article | Post-print: After Peer Review


Young HIV-exposed children are at high risk for TB infection. We performed QuantiFERON-TB Gold among HIV-exposed children in South Africa at enrolment and 1-year follow-up. The incidence of TB infection was high for HIV+ (11 cases per 100 child-years) and HIV-exposed uninfected children (15 cases per 100 child-years). QuantiFERON-TB Gold may identify HIV-exposed children at risk for TB disease progression.
Export to EndNote